Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma

  • Xi-Bao Zhang |
  • San-Quan Zhang Guangzhou Institute of Dermatology, China.
  • Chang-Xing Li Dongguan Institute of Dermatology, China.
  • Zhen-Ming Huang Guangzhou Institute of Dermatology, China.
  • Yu-Wu Luo Guangzhou Institute of Dermatology, .


Retinoids have been used for years as monotherapy and/or in combination for treatment and suppression of cutaneous malignancies in patients with basal cell nevus syndrome, xeroderma pigmentosum, or cutaneous T-cell lymphoma (CTCL) basal cell carcinoma (BCC). We report 4 cases with BCC confirmed by histopathology who were treated by short-term systemic acitretin combined with retinoic acid 0.1% cream. The 4 cases with BCC showed good response to the treatment without severe adverse effects during treatment and follow-up. The finding suggests that acitretin may be an appropriate treatment option for elderly patients who require less invasive treatment for BCC.


Download data is not yet available.
Case Reports
Acitretin, basal cell carcinoma
Abstract views: 5166

PDF: 563
HTML: 263
Share it
Bookmark and Share

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Zhang, X.-B., Zhang, S.-Q., Li, C.-X., Huang, Z.-M., & Luo, Y.-W. (2010). Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma. Dermatology Reports, 2(1), e4.

Most read articles by the same author(s)